PMID- 33998237
OWN - NLM
STAT- MEDLINE
DCOM- 20210806
LR  - 20220701
IS  - 0028-2685 (Print)
IS  - 0028-2685 (Linking)
VI  - 68
IP  - 4
DP  - 2021 Jul
TI  - Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients 
      with microsatellite stable and/or proficient mismatch repair metastatic 
      colorectal cancer: an observational pilot study.
PG  - 861-866
LID - 201228N1415 [pii]
LID - 10.4149/neo_2021_201228N1415 [doi]
AB  - This study was to investigate the efficacy and safety of regorafenib or 
      fruquintinib combined with camrelizumab in patients with microsatellite stable 
      (MSS) and/or proficient mismatch repair (pMMR) metastatic colorectal cancer 
      (mCRC). Medical records of MSS/pMMR mCRC patients who received regorafenib (80 
      mg) or fruquintinib (3 mg) once a day (21 days on/7 days off) plus camrelizumab 
      (200 mg) every three weeks in Yuhuangding Hospital between January 2020 and June 
      2020 were retrospectively collected. Follow-up data up to November 1st, 2020 was 
      gathered. The primary endpoint was the objective response rate (ORR) and disease 
      control rate (DCR). The safety profile was the secondary endpoint. A total of 16 
      patients were enrolled. The ORR was 25.0% (4/16) and the DCR was 62.5% (10/16). 
      The main adverse events (AEs) included reactive cutaneous capillary endothelial 
      proliferation (RCCEP) (81.3%), fatigue (43.8%), hypertension (37.5%), hand-foot 
      skin reaction (25.0%), and thyroid dysfunction (25.0%). Most AEs were grade 1 or 
      2, with only 1 patient of grade 3 liver dysfunction. All the AEs were ameliorated 
      by effective symptomatic treatment. Regorafenib or fruquintinib plus camrelizumab 
      exhibited promising efficacy in patients with MSS/pMMR mCRC. The toxicity was 
      moderate and manageable.
FAU - Jiang, Feng-E
AU  - Jiang FE
AD  - Department of Medical Oncology, Yantai Yuhuangding Hospital, Shandong, China.
FAU - Zhang, Hui-Juan
AU  - Zhang HJ
AD  - Department of Medical Oncology, Yantai Yuhuangding Hospital, Shandong, China.
FAU - Yu, Cai-Yan
AU  - Yu CY
AD  - Department of Medical Oncology, Yantai Yuhuangding Hospital, Shandong, China.
FAU - Liu, Ai-Na
AU  - Liu AN
AD  - Department of Medical Oncology, Yantai Yuhuangding Hospital, Shandong, China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20210517
PL  - Slovakia
TA  - Neoplasma
JT  - Neoplasma
JID - 0377266
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Benzofurans)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 0 (Quinazolines)
RN  - 24T2A1DOYB (regorafenib)
RN  - 49DXG3M5ZW (HMPL-013)
RN  - 73096E137E (camrelizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Benzofurans
MH  - *Colorectal Neoplasms/drug therapy/genetics
MH  - *DNA Mismatch Repair/genetics
MH  - Humans
MH  - Microsatellite Repeats
MH  - Phenylurea Compounds
MH  - Pilot Projects
MH  - Pyridines
MH  - Quinazolines
MH  - Retrospective Studies
EDAT- 2021/05/18 06:00
MHDA- 2021/08/07 06:00
CRDT- 2021/05/17 08:40
PHST- 2020/12/28 00:00 [received]
PHST- 2021/03/17 00:00 [accepted]
PHST- 2021/05/18 06:00 [pubmed]
PHST- 2021/08/07 06:00 [medline]
PHST- 2021/05/17 08:40 [entrez]
AID - 201228N1415 [pii]
AID - 10.4149/neo_2021_201228N1415 [doi]
PST - ppublish
SO  - Neoplasma. 2021 Jul;68(4):861-866. doi: 10.4149/neo_2021_201228N1415. Epub 2021 
      May 17.